P045 Attendance at bi-annual hepatocellular cancer surveillance, in a hepatitis C cirrhosis cohort, – Does deprivation matter?

Hepatitis B virus (HBV) and Hepatitis C virus (HCV) are the cause of many different forms of heart disease worldwide and yet few cardiologists are aware of it as an etiology of heart disease, or its treatment. The burden of HBV and HCV derived heart diseases are global, with a higher prevalence in Asia, Africa, and low- and middle-income countries. The study showed that in more than 10% of Japanese patients, their cardiomyopathies are associated with HCV infection. More recently, it is found in the USA that up to 15% of patients with heart failure with myocarditis have been associated HCV infection. In contrast, in China 79% of patients with hepatocellular cancer and 37% of hepatitis C patients have heart disease, as detected by measuring a proven and sensitive biomarker of heart disease, NT-proBNP. In Pakistan, 17% of hepatitis C patients have heart diseases, as measured by this metric (NT-proBNP). Based on these data, 3% of 6.6 billion (198 million) persons worldwide are infected with HCV and 1737% (3473 million) persons are suffering from HCV-derived heart diseases. These figures may be comparable to the number of patients with hepatitis C. HCV infection causes only hepatitis in some patients, only heart diseases in some patients, and both hepatitis and heart diseases in other patients. A global network is required to establish methods to detect heart diseases caused by infectious agents. Other goals for the network are the expansion of preventive and therapeutic programs in under privileged countries. DOI: http://dx.doi.org/10.3329/uhj.v8i2.16084 University Heart Journal Vol. 8, No. 2, July 2012

Download Full-text

Sunitinib Versus Sorafenib in Advanced Hepatocellular Cancer: Results of a Randomized Phase III Trial

Journal of Clinical Oncology ◽

10.1200/jco.2012.45.8372 ◽

2013 ◽

Vol 31 (32) ◽

pp. 4067-4075 ◽

Cited By ~ 409

Author(s):

Ann-Lii Cheng ◽

Yoon-Koo Kang ◽

Deng-Yn Lin ◽

Joong-Won Park ◽

Masatoshi Kudo ◽

...

Keyword(s):

Hepatitis C ◽

Hepatitis B ◽

Hepatocellular Cancer ◽

Progression Free Survival ◽

Phase Iii ◽

Severe Toxicity ◽

Open Label ◽

Phase Iii Trial ◽

Open Label Phase ◽

Hand Foot Syndrome

Purpose Open-label, phase III trial evaluating whether sunitinib was superior or equivalent to sorafenib in hepatocellular cancer. Patients and Methods Patients were stratified and randomly assigned to receive sunitinib 37.5 mg once per day or sorafenib 400 mg twice per day. Primary end point was overall survival (OS). Results Early trial termination occurred for futility and safety reasons. A total of 1,074 patients were randomly assigned to the study (sunitinib arm, n = 530; sorafenib arm, n = 544). For sunitinib and sorafenib, respectively, median OS was 7.9 versus 10.2 months (hazard ratio [HR], 1.30; one-sided P = .9990; two-sided P = .0014); median progression-free survival (PFS; 3.6 v 3.0 months; HR, 1.13; one-sided P = .8785; two-sided P = .2286) and time to progression (TTP; 4.1 v 3.8 months; HR, 1.13; one-sided P = .8312; two-sided P = .3082) were comparable. Median OS was similar among Asian (7.7 v 8.8 months; HR, 1.21; one-sided P = .9829) and hepatitis B–infected patients (7.6 v 8.0 months; HR, 1.10; one-sided P = .8286), but was shorter with sunitinib in hepatitis C–infected patients (9.2 v 17.6 months; HR, 1.52; one-sided P = .9835). Sunitinib was associated with more frequent and severe adverse events (AEs) than sorafenib. Common grade 3/4 AEs were thrombocytopenia (29.7%) and neutropenia (25.7%) for sunitinib; hand-foot syndrome (21.2%) for sorafenib. Discontinuations owing to AEs were similar (sunitinib, 13.3%; sorafenib, 12.7%). Conclusion OS with sunitinib was not superior or equivalent but was significantly inferior to sorafenib. OS was comparable in Asian and hepatitis B–infected patients. OS was superior in hepatitis C–infected patients who received sorafenib. Sunitinib-treated patients reported more frequent and severe toxicity.

Download Full-text

Correlation of soluble interleukin-2 receptor levels with severity of chronic hepatitis C virus liver injury and development of hepatocellular cancer

Surgery ◽

10.1016/s0039-6060(96)80247-9 ◽

1996 ◽

Vol 120 (1) ◽

pp. 100-105 ◽

Cited By ~ 12

Author(s):

Francesco Izzo ◽

Steven Curley ◽

Patrizia Maio ◽

Enrico Leonardi ◽

Luca Imparato ◽

...

Keyword(s):

Chronic Hepatitis ◽

Hepatitis C Virus ◽

Hepatitis C ◽

Liver Injury ◽

Chronic Hepatitis C ◽

Interleukin 2 ◽

Hepatocellular Cancer ◽

Interleukin 2 Receptor ◽

Chronic Hepatitis C Virus ◽

Soluble Interleukin 2 Receptor

Download Full-text

Forecasted impacts of a sofosbuvir-based national hepatitis C treatment programme on Egypt’s hepatocellular cancer epidemic: simulation of alternatives

BMJ Global Health ◽

10.1136/bmjgh-2017-000572 ◽

2018 ◽

Vol 3 (2) ◽

pp. e000572 ◽

Cited By ~ 1

Author(s):

Wenkang Ma ◽

Amr S Soliman ◽

Wagida A Anwar ◽

Ahmed Hablas ◽

Tamer B El Din ◽

...

Keyword(s):

Hepatitis C ◽

Treatment Success ◽

Hepatocellular Cancer ◽

Sensitivity Analyses ◽

Annual Number ◽

Treatment Programme ◽

Epidemic Period ◽

Hcv Transmission ◽

New Treatment ◽

Liver Cancer Prevention

BackgroundEgypt is experiencing a hepatocellular cancer (HCC) epidemic due to widespread hepatitis C virus (HCV) transmission. The use of sofosbuvir-related therapies producing improved treatment success has permitted an updated, nationwide, HCV treatment programme with expanded coverage. This study simulated the multidecade impacts of the new treatment programme on hepatitis and HCC.MethodsA Markov model of HCV infection and treatment analysed the HCV-related HCC epidemic between 2009 and 2050, using parameters based on peer-reviewed studies and expert opinion. Comparing the ‘new’ and ‘old’ scenarios, and with the old treatment programme being replaced or not by the new programme in 2015, the annual number, prevalence and incidence of HCC were simulated for representative Egypt populations including HCV-infected patients aged 15–59 years in 2008, healthy people aged 5–59 years in 2008 and 5-year-old children cohorts entering the population each year beginning in 2009. Averted HCC cases were calculated, and sensitivity analyses were performed.ResultsCompared with the old scenario, the estimated number, prevalence and incidence of future HCC cases in the new scenario would peak earlier and at lower levels in 2025 (~29 000), 2023 (~28/100 000) and 2022 (~14/100 000), respectively. The new treatment programme is estimated to avert ~956 000 HCC cases between 2015 and 2050.DiscussionBy reducing cancer cases and shortening the peak epidemic period, the new programme should substantially diminish the HCC epidemic across Egypt. Our timeline forecast for Egypt’s HCC epidemic, and evaluation of various disease and programme components, should be useful to other countries that are developing policies to address HCV-related liver cancer prevention.

Download Full-text

A descriptive study of racial inequalities in mortality from hepatocellular cancer before and after licensure of lifesaving drugs for hepatitis C virus in the United States

EClinicalMedicine ◽

10.1016/j.eclinm.2020.100350 ◽

2020 ◽

Vol 22 ◽

pp. 100350 ◽

Cited By ~ 1

Author(s):

Robert S Levine ◽

Maria C Mejia ◽

Jason L Salemi ◽

Sandra J Gonzalez ◽

Muktar H Aliyu ◽

...

Keyword(s):

United States ◽

Hepatitis C Virus ◽

Hepatitis C ◽

Hepatocellular Cancer ◽

Descriptive Study ◽

The United States ◽

Racial Inequalities ◽

Before And After ◽

Inequalities In Mortality

Download Full-text

Comparison of Hispanic and non-Hispanic patients with HCC.

Journal of Clinical Oncology ◽

10.1200/jco.2014.32.30_suppl.294 ◽

2014 ◽

Vol 32 (30_suppl) ◽

pp. 294-294 ◽

Cited By ~ 1

Author(s):

Atinuke Babalola ◽

Rebecca A. Miksad ◽

Olubunmi Oladunjoye ◽

Ugonna Nwosu ◽

Nelsy Castro-Webb ◽

...

Keyword(s):

Metabolic Syndrome ◽

Hepatitis C ◽

Medical Center ◽

Private Insurance ◽

Hepatocellular Cancer ◽

Hispanic Patients ◽

Chi Squared ◽

Low Hdl ◽

Disease Specific Mortality ◽

The U.S

294 Background: In the U.S., Hispanics have a higher incidence of hepatocellular cancer (HCC) and higher disease-specific mortality. The country of origin for Hispanics varies throughout the U.S. However, little is known about Hispanics with HCC in the Northeast. We compared Hispanic and non-Hispanic patients with HCC at a Boston teaching hospital. Methods: Hispanic patients with HCC seen at Beth Israel Deaconess Medical Center (BIDMC) from 1998-2012 were identified in our database. Ethnicity was determined from demographic and language preference information in electronic medical records and supplemented by comparing surnames with the 1990 Census Spanish Surname List. The comparison group was identified by randomly choosing non-Hispanic patients diagnosed the same years as Hispanic patients. We compared both groups using Chi Squared test. Results: 59 Hispanic and 89 non-Hispanic patients with HCC were included in the analysis. The majority (48%) of Hispanic HCC patients were Puerto Rican. Although the median age at diagnosis was similar (59.1 vs 60.3 years for Hispanics and non-Hispanics), there were more women in the Hispanic cohort (28.8% vs 12.4% p0.012). Hispanics had greater odds of not having private insurance (OR 4.24, 95%CI: 2.101, 8.554). Evaluation of HCC risk factors revealed Hispanics were significantly more likely to have hepatitis C (OR 3.68, 95% CI: 1.830, 7.420). In addition, the incidence of Metabolic Syndrome was significantly higher for Hispanics (44.7% vs. 21.7% p0.025). Although individual components of metabolic syndrome were higher in Hispanics, they were not statistically significant: hypertension (52.5% vs 40.4%), Diabetes Mellitus (39% vs 25%), BMI ≥ 30 (39% vs 27%), hypertrigylceridemia (57% vs 52%) and low HDL levels (50% vs 41%). Hispanics were more likely to have received Transarterial Chemoembolization (TACE) and Radiofrequency ablation (RFA) treatments (OR 2.48, 95% CI: 1.261, 4.858). Conclusions: Hispanic HCC patients at BIDMC were more likely to have hepatitis C, metabolic syndrome and to be female than their non-Hispanic counterparts. Outreach to Hispanic communities to identify patients with hepatitis C and metabolic syndrome, particularly in women, may improve HCC prevention, screening and treatment outcomes.

Download Full-text